- In patients with myelodysplastic syndrome (MDS), development of secondary acute myeloid leukemia (sAML) is associated with inferior prognosis.
- Consideration of select demographic factors may help inform risk assessment.
Why this matters
- sAML is responsible for up to one-half of disease-associated deaths in patients with MDS.
- Study of outcomes in patients with MDS based on the Surveillance, Epidemiology, and End Results database.
- Patient stratification: aged ≤40 years vs >40 years.
- Funding: Science and Technology Department of Zhejiang Province; Medical and Health Science and Technology Plan of Zhejiang Province; Public Technology Research Projects of Yiwu, China; Key Medical Discipline of Yiwu.
- 3.7% of younger patients and 2.5% of older patients developed sAML (P=.039); median time to transformation was 4.04 and 13.1 months, respectively (P<.001>
- Significantly shorter median OS and median cancer-specific survival (CSS) in those who developed sAML for both age groups (all P<.001>
- In multivariate analysis, favorable prognostic factors for OS in older patients with MDS included:
- Female sex: adjusted HR (aHR), 0.806; 95% CI, 0.783-0.830; P<.001.>
- Black race: aHR, 0.929; 95% CI, 0.881-0.979; P=.006.
- Married status: aHR, 0.811; 95% CI, 0.773-0.852; P<.001.>
- Retrospective analysis.